Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study

Prev Med. 2016 Sep:90:52-8. doi: 10.1016/j.ypmed.2016.06.041. Epub 2016 Jun 28.

Abstract

Human papillomaviruses (HPV) are involved in the development of anogenital and head and neck cancers. The purpose of this study was to assess the risk of developing a second primary cancer (SPC) after a first potentially-HPV-related cancer, and to analyze the sites where SPCs most frequently occurred in these patients. All patients with a first cancer diagnosed between 1989 and 2004, as recorded by 10 French cancer registries, were followed up until December 31, 2007. Only invasive potentially-HPV-related cancers (namely, cervical, vagina, vulva, anal canal, penile, oropharynx, tongue and tonsil) were included. Standardized Incidence Ratios (SIRs) were calculated to assess the risk of SPC. A multivariate Poisson regression model was used to model SIRs separately by gender, adjusted for the characteristics of the first cancer. 10,127 patients presented a first potentially-HPV-related cancer. The overall SIR was 2.48 (95% CI, 2.34-2.63). The SIR was 3.59 (95% CI, 3.33-3.86) and 1.61 (95% CI, 1.46-1.78) in men and women respectively. The relative risk of potentially-HPV-related SPC was high among these patients (SIR=13.74; 95% CI, 8.80-20.45 and 6.78; 95% CI, 4.61-9.63 for men and women, respectively). Women diagnosed in the most recent period (2000-2004) showed a 40% increase of their relative risk of SPC as compared with women diagnosed between 1989 and 1994 (ratio of SIRs=1.40; 95% CI, 1.06-1.85). HPV cancer survivors face an increased risk of SPC, especially second cancer. Clinicians may consider this increased risk of developing HPV-related SPC during follow-up to improve subsequent cancer prevention in these patients.

Keywords: Human papillomavirus; Neoplasms, second primary; Registries; Risk assessment.

MeSH terms

  • Female
  • France
  • Head and Neck Neoplasms / epidemiology
  • Humans
  • Incidence
  • Neoplasms, Second Primary / epidemiology*
  • Papillomaviridae / isolation & purification
  • Papillomavirus Infections / complications*
  • Population Surveillance / methods*
  • Registries
  • Retrospective Studies
  • Risk Factors
  • Urogenital Neoplasms / epidemiology